Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 0.22
GLAXF's Cash to Debt is ranked higher than
53% of the 926 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. GLAXF: 0.22 )
GLAXF' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 0.22

Equity to Asset 0.13
GLAXF's Equity to Asset is ranked lower than
52% of the 833 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. GLAXF: 0.13 )
GLAXF' s 10-Year Equity to Asset Range
Min: 0.05   Max: 0.4
Current: 0.13

0.05
0.4
Interest Coverage 9.68
GLAXF's Interest Coverage is ranked higher than
58% of the 566 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 160.63 vs. GLAXF: 9.68 )
GLAXF' s 10-Year Interest Coverage Range
Min: 0.81   Max: 28.06
Current: 9.68

0.81
28.06
F-Score: 6
Z-Score: 2.20
M-Score: -2.52
WACC vs ROIC
6.83%
22.47%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 22.54
GLAXF's Operating margin (%) is ranked higher than
85% of the 875 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.10 vs. GLAXF: 22.54 )
GLAXF' s 10-Year Operating margin (%) Range
Min: 1.68   Max: 36.94
Current: 22.54

1.68
36.94
Net-margin (%) 17.63
GLAXF's Net-margin (%) is ranked higher than
84% of the 875 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.05 vs. GLAXF: 17.63 )
GLAXF' s 10-Year Net-margin (%) Range
Min: 5.76   Max: 23.94
Current: 17.63

5.76
23.94
ROE (%) 68.04
GLAXF's ROE (%) is ranked higher than
99% of the 895 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.83 vs. GLAXF: 68.04 )
GLAXF' s 10-Year ROE (%) Range
Min: 17.3   Max: 244.21
Current: 68.04

17.3
244.21
ROA (%) 10.35
GLAXF's ROA (%) is ranked higher than
84% of the 930 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.82 vs. GLAXF: 10.35 )
GLAXF' s 10-Year ROA (%) Range
Min: 3.84   Max: 26.32
Current: 10.35

3.84
26.32
ROC (Joel Greenblatt) (%) 58.14
GLAXF's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 925 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.02 vs. GLAXF: 58.14 )
GLAXF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 5.44   Max: 141.62
Current: 58.14

5.44
141.62
Revenue Growth (3Y)(%) -0.90
GLAXF's Revenue Growth (3Y)(%) is ranked higher than
63% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. GLAXF: -0.90 )
GLAXF' s 10-Year Revenue Growth (3Y)(%) Range
Min: -1.5   Max: 15.3
Current: -0.9

-1.5
15.3
EBITDA Growth (3Y)(%) 17.30
GLAXF's EBITDA Growth (3Y)(%) is ranked higher than
84% of the 676 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.40 vs. GLAXF: 17.30 )
GLAXF' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -11.8   Max: 17.3
Current: 17.3

-11.8
17.3
EPS Growth (3Y)(%) 51.40
GLAXF's EPS Growth (3Y)(%) is ranked higher than
95% of the 667 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.10 vs. GLAXF: 51.40 )
GLAXF' s 10-Year EPS Growth (3Y)(%) Range
Min: -30.2   Max: 51.4
Current: 51.4

-30.2
51.4
» GLAXF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with GLAXF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 17.90
GLAXF's P/E(ttm) is ranked higher than
92% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 48.60 vs. GLAXF: 17.90 )
GLAXF' s 10-Year P/E(ttm) Range
Min: 10.16   Max: 40.41
Current: 17.9

10.16
40.41
Forward P/E 16.95
GLAXF's Forward P/E is ranked higher than
90% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 58.14 vs. GLAXF: 16.95 )
N/A
PE(NRI) 18.10
GLAXF's PE(NRI) is ranked higher than
92% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 48.50 vs. GLAXF: 18.10 )
GLAXF' s 10-Year PE(NRI) Range
Min: 10.17   Max: 41.19
Current: 18.1

10.17
41.19
P/B 14.60
GLAXF's P/B is ranked higher than
51% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.57 vs. GLAXF: 14.60 )
GLAXF' s 10-Year P/B Range
Min: 5.48   Max: 14.79
Current: 14.6

5.48
14.79
P/S 3.20
GLAXF's P/S is ranked higher than
78% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.01 vs. GLAXF: 3.20 )
GLAXF' s 10-Year P/S Range
Min: 1.94   Max: 4.9
Current: 3.2

1.94
4.9
PFCF 21.30
GLAXF's PFCF is ranked higher than
93% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. GLAXF: 21.30 )
GLAXF' s 10-Year PFCF Range
Min: 8.21   Max: 41.33
Current: 21.3

8.21
41.33
POCF 14.55
GLAXF's POCF is ranked higher than
90% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 36.53 vs. GLAXF: 14.55 )
GLAXF' s 10-Year POCF Range
Min: 6.64   Max: 20.67
Current: 14.55

6.64
20.67
EV-to-EBIT 16.75
GLAXF's EV-to-EBIT is ranked higher than
89% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.09 vs. GLAXF: 16.75 )
GLAXF' s 10-Year EV-to-EBIT Range
Min: 7.7   Max: 240.2
Current: 16.75

7.7
240.2
PEG 12.07
GLAXF's PEG is ranked higher than
83% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. GLAXF: 12.07 )
GLAXF' s 10-Year PEG Range
Min: 0.23   Max: 437.2
Current: 12.07

0.23
437.2
Shiller P/E 17.40
GLAXF's Shiller P/E is ranked higher than
95% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 103.75 vs. GLAXF: 17.40 )
GLAXF' s 10-Year Shiller P/E Range
Min: 10.59   Max: 20.59
Current: 17.4

10.59
20.59
Current Ratio 0.97
GLAXF's Current Ratio is ranked lower than
51% of the 900 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.36 vs. GLAXF: 0.97 )
GLAXF' s 10-Year Current Ratio Range
Min: 0.97   Max: 1.78
Current: 0.97

0.97
1.78
Quick Ratio 0.69
GLAXF's Quick Ratio is ranked lower than
51% of the 900 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. GLAXF: 0.69 )
GLAXF' s 10-Year Quick Ratio Range
Min: 0.68   Max: 1.42
Current: 0.69

0.68
1.42
Days Inventory 191.79
GLAXF's Days Inventory is ranked higher than
63% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 153.90 vs. GLAXF: 191.79 )
GLAXF' s 10-Year Days Inventory Range
Min: 145.16   Max: 321.53
Current: 191.79

145.16
321.53
Days Sales Outstanding 79.77
GLAXF's Days Sales Outstanding is ranked higher than
76% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 94.97 vs. GLAXF: 79.77 )
GLAXF' s 10-Year Days Sales Outstanding Range
Min: 54.62   Max: 114.48
Current: 79.77

54.62
114.48

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 5.40
GLAXF's Dividend Yield is ranked higher than
98% of the 532 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.44 vs. GLAXF: 5.40 )
GLAXF' s 10-Year Dividend Yield Range
Min: 2.72   Max: 5.91
Current: 5.4

2.72
5.91
Dividend Payout 0.96
GLAXF's Dividend Payout is ranked higher than
99% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.43 vs. GLAXF: 0.96 )
GLAXF' s 10-Year Dividend Payout Range
Min: 0.38   Max: 4.69
Current: 0.96

0.38
4.69
Dividend growth (3y) 6.40
GLAXF's Dividend growth (3y) is ranked higher than
82% of the 359 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.40 vs. GLAXF: 6.40 )
GLAXF' s 10-Year Dividend growth (3y) Range
Min: -12.6   Max: 20.8
Current: 6.4

-12.6
20.8
Yield on cost (5-Year) 7.43
GLAXF's Yield on cost (5-Year) is ranked higher than
96% of the 541 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. GLAXF: 7.43 )
GLAXF' s 10-Year Yield on cost (5-Year) Range
Min: 3.74   Max: 8.14
Current: 7.43

3.74
8.14
Share Buyback Rate 1.40
GLAXF's Share Buyback Rate is ranked higher than
96% of the 662 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.90 vs. GLAXF: 1.40 )
GLAXF' s 10-Year Share Buyback Rate Range
Min: 3.6   Max: -20
Current: 1.4

Valuation & Return

vs
industry
vs
history
Price/DCF (Projected) 1.60
GLAXF's Price/DCF (Projected) is ranked higher than
91% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.24 vs. GLAXF: 1.60 )
GLAXF' s 10-Year Price/DCF (Projected) Range
Min: 0.97   Max: 21.79
Current: 1.6

0.97
21.79
Price/Median PS Value 1.10
GLAXF's Price/Median PS Value is ranked higher than
83% of the 967 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.36 vs. GLAXF: 1.10 )
GLAXF' s 10-Year Price/Median PS Value Range
Min: 0.69   Max: 3.21
Current: 1.1

0.69
3.21
Earnings Yield (Greenblatt) 6.10
GLAXF's Earnings Yield (Greenblatt) is ranked higher than
89% of the 927 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. GLAXF: 6.10 )
GLAXF' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.4   Max: 12.9
Current: 6.1

0.4
12.9
Forward Rate of Return (Yacktman) 6.91
GLAXF's Forward Rate of Return (Yacktman) is ranked higher than
75% of the 527 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.94 vs. GLAXF: 6.91 )
GLAXF' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4   Max: 67.3
Current: 6.91

4
67.3

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:JNJ, PFE, RHHBY, NVS, ABT » details
Traded in other countries:GSK.UK, GSK.USA, GS7A.Germany, GS7.Germany, GSK N.Mexico, GSK.Argentina, GSK.Switzerland,
GlaxoSmithKline PLC incorporated in United Kingdom. The Company creates, discoveres, develops, manufactures and markets pharmaceutical products including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's principal pharmaceutical products include medicines in the following therapeutic areas: respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, oncology and emesis, dermatology, rare diseases, immuno-inflammation, vaccines and HIV. The Company is a science-led global healthcare company that researches and develops a broad range of innovative products in three primary areas of pharmaceuticals, vaccines and consumer healthcare. Its Pharmaceuticals business develops and makes medicines to treat a broad range of acute and chronic diseases. Its portfolio is made up of both patent-protected and off patent medicines. Its products include treatment for Infectious Diseases, Cancer, Epilepsy, Heart Disease, Asthma and Chronic obstructive pulmonary disease, and HIV/AIDS. Its Vaccine business has approximately 900 million doses distributed to 170 countries in 2012. It produces paediatric and adult vaccines to prevent a range of infectious diseases including: Hepatitis A and B, Diphtheria, Tetanus and Whooping cough, Measles, Mumps and Rubella, Polio, Typhoid, Influenza, Bacterial Meningitis. The consumer healthcare business, markets consumer health products based on scientific innovation. Its products main categories are: Oral care, Nutritional, Total wellness, and Skin health. Its barands include Sensodyne, Panadol and Horlicks. Its drinks brands are Lucozade and Ribena. The Oral Care brands, alli and Abreva.
» More Articles for GLAXF

Headlines

Articles On GuruFocus.com
Novartis Gets FTC Nod To Buyout Glaxo Smithkline’s Cancer Drugs Feb 25 2015 
Dodge & Cox 2014 Equity Year in Review Feb 19 2015 
Bestinfond's Top 5 New Buys During Q4 Feb 03 2015 
Can GlaxoSmithKline Continue Striving in the Face of World Challenges? Jan 30 2015 
Tumor Drug Takes The Focus At OncoMed Pharmaceuticals Jan 29 2015 
Gilead Sciences Still has More Upside Jan 22 2015 
Johnson & Johnson Riding High On Ebola Vaccines Jan 21 2015 
set Jan 11 2015 
tester Dec 18 2014 
Weekly 3-Year Low Highlights: RDS.B, GSK, WPZ, CLR Dec 14 2014 

More From Other Websites
GSK-Novartis deal 'a model' for industry Mar 02 2015
GSK and Novartis complete deals to reshape both drugmakers Mar 02 2015
GSK and Novartis complete deals to reshape both drugmakers Mar 02 2015
Britain's secret science powerhouse Mar 02 2015
UK drug manufacture drops by a quarter Mar 01 2015
Cutting-edge pharma is in Neil Woodford's investment DNA Mar 01 2015
China says to implement drug distribution reforms Feb 28 2015
Ireland's Malin seeks up to 325 mln euros in biotech IPO Feb 27 2015
GSK chief's pay halved after China scandal Feb 26 2015
GlaxoSmithKline bribery scandal led to 13-fold increase in China whistleblower reports Feb 26 2015
GSK's new chairman Hampton to take charge in May Feb 26 2015
GSK's new chairman Hampton to take charge in May Feb 26 2015
RBS bank posts £3.5bn annual loss on US writedown Feb 26 2015
RBS to slash investment banking after huge loss Feb 26 2015
Howard Davies set to be confirmed as RBS chairman -sources Feb 25 2015
GSK set to complete $20 bln Novartis asset swap next week Feb 25 2015
HSBC, tax and why good companies do bad things Feb 25 2015
London stocks index hits record highs Feb 24 2015
Wealth of experience prepares Sir Howard Davies for new RBS role Feb 23 2015
Novartis AG wins approval to buy GSK cancer drugs, with conditions Feb 23 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK